ANDA 65197, held by Wockhardt. Cefotaxime Sodium.
As of Nov 21, 2026, ANDA 65197 (Cefotaxime, Cefotaxime Sodium), held by Wockhardt, was first approved by FDA on Aug 29, 2006, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 29, 2006 | Original application | Approved | None posted |
| CefotaximeEQ 1GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Cefotaxime SodiumEQ 500MG BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Cefotaxime SodiumEQ 2GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| May 10, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 20, 2008 | Supplement 2Labeling | Approved | None posted |
| Aug 29, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters